Innovation Pharmaceuticals Inc. (IPIX)
| Market Cap | 111.68M |
| Revenue (ttm) | 23,000 |
| Net Income (ttm) | -9.82M |
| Shares Out | 418.07M |
| EPS (ttm) | -0.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $0.2575 |
| Previous Close | $0.2600 |
| Change ($) | -0.0025 |
| Change (%) | -0.96% |
| Day's Open | 0.2689 |
| Day's Range | 0.2530 - 0.2699 |
| Day's Volume | 745,440 |
| 52-Week Range | 0.1160 - 0.6500 |
WAKEFIELD, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that Brilacidin, the Company's d...
WAKEFIELD, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that antiviral data related to B...
WAKEFIELD, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that an independent Data Monitor...
WAKEFIELD, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report today that a Machine Learni...
WAKEFIELD, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today reports that eight sites are now participa...
WAKEFIELD, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announces today that the Company's Phase 2 clinic...
Phase 2 clinical trial of Brilacidin for COVID-19 anticipated to commence this month Phase 2 clinical trial of Brilacidin for COVID-19 anticipated to commence this month
WAKEFIELD, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces additional independent preliminar...
About IPIX
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. It develops Brilacidin, a lead drug compound for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company also develops Kevetrin, a lead anti-cancer compound for treating ovarian cancer. It has license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Cha... [Read more...]
| Industry Biotechnology | |
| Stock Exchange OTCMKTS | Ticker Symbol IPIX |